Eli Lilly: psoriasis drug beats rival in trial
(CercleFinance.com) - Eli Lilly's experimental drug mirikizumab helped to reduce symptoms in patients with moderate-to-severe plaque psoriasis better than Novartis' Cosentyx, the US drugmaker said on Friday.
The monoclonal antibody met the primary and all key secondary endpoints versus placebo at week 16, and all key secondary endpoints versus Cosentyx at week 16 and week 52, Lilly said.
The drug showed in particular superiority in skin clearance at week 52, the company said.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The monoclonal antibody met the primary and all key secondary endpoints versus placebo at week 16, and all key secondary endpoints versus Cosentyx at week 16 and week 52, Lilly said.
The drug showed in particular superiority in skin clearance at week 52, the company said.
Copyright (c) 2020 CercleFinance.com. All rights reserved.